曲美他嗪在缺血性心肌病心力衰竭治疗中临床疗效分析

Analysis of Clinical Efficacy of Trimetazidine in the Treatment of Ischemic Cardiomyopathy and Heart Failure

目的探讨对缺血性心肌病心力衰竭患者采用曲美他嗪药物进行治疗后获得临床效果。方法选取2018年1月—2020年12月该院收治的58例缺血性心肌病心力衰竭患者进行药物治疗研究;随机分为参照组(采用常规疗法展开疾病治疗)和研究组(采用常规疗法+曲美他嗪药物展开疾病治疗),各29例;比较两组患者治疗总有效率、血浆BNP水平、心功能指标[左室收缩末期内径(LVESD)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)]水平。结果研究组治疗总有效率(93.10%)高于参照组(68.97%),差异有统计学意义(χ^(2)=5.497,P<0.05);治疗前,研究组血浆BNP水平(844.59±80.62)pg/mL同参照组(845.59±80.99)pg/mL比较,差异无统计学意义(t=0.047,P>0.05);治疗后,研究组血浆BNP水平(531.91±50.53)pg/mL低于参照组(893.46±50.59)pg/mL,差异有统计学意义(t=27.229,P<0.05);治疗前,研究组LVESD(47.15±3.29)mm、LVEF(36.49±3.61)%、LVEDD(59.89±4.55)mm同参照组LVESD(46.89±3.56)mm、LVEF(36.81±3.23)%、LVEDD(60.79±4.79)mm比较,差异无统计学意义(t=0.288、0.355、0.733,P>0.05);治疗后,研究组LVESD(37.12±3.15)mm、LVEDD(49.91±4.61)mm低于参照组的LVESD(42.25±3.09)mm、LVEDD(54.52±4.71)mm,研究组LVEF(48.06±4.21)%高于参照组LVEF(42.52±3.66)%,差异有统计学意义(t=6.260、3.766、5.347,P<0.05)。结论曲美他嗪药物有效应用后,观察患者治疗总有效率、血浆BNP水平、心功能指标水平,均获得明显改善,可促进缺血性心肌病心力衰竭患者总体用药效果以及预后效果显著提升。

Objective To explore the clinical effects of trimetazidine in patients with ischemic cardiomyopathy and heart failure. Methods From January 2018 to December 2020, 58 patients with ischemic cardiomyopathy and heart failure admitted to the hospital were selected for drug treatment research. Randomly divided into the reference group(using conventional therapies for disease treatment) and the study group(using conventional therapies + trimetazidine drugs for disease treatment), each with 29 cases. The total effective rate of treatment, plasma BNP levels, and cardiac function indexes[left ventricular end systolic diameter(LVESD), left ventricular ejection fraction(LVEF), left ventricular end diastolic diameter(LVEDD)] levels were compared between the two groups. Results The total effective rate of treatment in the study group(93.10%) was higher than that of the reference group(68.97%), and the difference was statistically significant(χ^(2)=5.497, P<0.05). Before treatment, the plasma BNP level(844.59±80.62) pg/mL of the study group was compared with the reference group(845.59±80.99) pg/mL, and the difference was not statistically significant(t=0.047, P>0.05). After treatment, the plasma BNP level(531.91±50.53) pg/mL of the study group was lower than the reference group(893.46±50.59) pg/mL, the difference was statistically significant(t=27.229, P<0.05). Before treatment, LVESD(47.15±3.29) mm, LVEF(36.49±3.61)%, LVEDD(59.89±4.55) mm in the study group were the same as those in the reference group LVESD(46.89 ±3.56) mm, LVEF(36.81 ±3.23)%, LVEDD(60.79 ±4.79) mm, the difference was not statistically significant(t=0.288, 0.355, 0.733, P>0.05). After treatment, the LVESD(37.12±3.15) mm and LVEDD(49.91±4.61) mm of the study group were lower than those of the reference group(42.25 ±3.09) mm and LVEDD(54.52±4.71) mm, and the study group LVEF(48.06±4.21)% was higher than the reference group(42.52±3.66)%, the difference was statistically significant(t =6.260, 3.766, 5.347, P <0.05). Conclusion After the effective application of trimetazidine, the total effective rate of treatment, plasma BNP level, and cardiac function index level of patients were observed to be significantly improved, which can promote the overall medication effect and prognosis of patients with ischemic cardiomyopathy and heart failure.